Flucytosine: Updated recommendations for the use in patients with dihydropyrimidine dehydrogenase (DPD) deficiency

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Active substance
Flucytosine
Procedure number
EMEA/H/A-31/1481
Regulatory outcome
Variation
DHPC type
Referral - Article 31
Referral name
Fluorouracil and fluorouracil related substances (capecitabine, tegafur and flucytosine) containing medicinal products
Human ATC code
J02AX01
Dissemination date
04/06/2020

How useful was this page?

Add your rating